Last $16.45 USD
Change Today +2.24 / 15.76%
Volume 16.5M
ACHN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 10:06 AM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

achillion pharmaceuticals (ACHN) Snapshot

Open
$15.20
Previous Close
$14.21
Day High
$16.74
Day Low
$14.56
52 Week High
12/22/14 - $16.74
52 Week Low
05/7/14 - $2.45
Market Cap
1.6B
Average Volume 10 Days
4.7M
EPS TTM
$-0.63
Shares Outstanding
100.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACHILLION PHARMACEUTICALS (ACHN)

achillion pharmaceuticals (ACHN) Related Businessweek News

No Related Businessweek News Found

achillion pharmaceuticals (ACHN) Details

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and resistant bacterial infections. The company’s drug candidates for treating chronic HCV infection comprise Sovaprevir, a NS3/4A protease inhibitor, which has completed a Phase IIa clinical trial; ACH-3102, a NS5A inhibitor that is in Phase IIa clinical trial; ACH-3422, a NS5B nucleotide polymerase inhibitor, which has completed preclinical studies; and ACH-2684, a NS3/4A protease inhibitor that has completed Phase Ia and Ib clinical trials. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, an antibacterial drug candidate that is delivered topically or locally. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

61 Employees
Last Reported Date: 03/7/14
Founded in 1998

achillion pharmaceuticals (ACHN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $435.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $326.4K
Chief Compliance Officer and Executive Vice P...
Total Annual Compensation: $334.4K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $313.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $256.7K
Compensation as of Fiscal Year 2013.

achillion pharmaceuticals (ACHN) Key Developments

Achillion Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 11:30 AM

Achillion Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 11:30 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Milind S. Deshpande, Chief Executive Officer, President and Director.

Achillion Reports Updates from an Ongoing Interferon-Free, Ribavirin-Free, Phase 2 Open-Label, Randomized, Partial-Crossover Study

Achillion reported updated interim results from an ongoing interferon-free, ribavirin-free, Phase 2 open-label, randomized, partial-crossover study to evaluate the efficacy, safety, and tolerability of eight weeks or six weeks of ACH-3102 and sofosbuvir, a marketed nucleotide polymerase inhibitor, without ribavirin, in treatment-naïve genotype 1 HCV-infected patients. The primary objective of the study is determination of sustained viral response 12 weeks (SVR12) after the completion of therapy. Eighteen patients were enrolled, including six observational patients. Twelve patients completed eight weeks of treatment consisting of 50 mg of ACH-3102 and 400 mg of sofosbuvir administered once daily while observational patients received no drug during this phase of the trial. Of the 12 patients treated, 100% (n=12/12) achieved SVR12. Of the 12 patients treated in this study, nine of 12 patients had a baseline viral load substantially greater than 6 million IU/ml at baseline. No on-treatment viral breakthrough or post-treatment viral relapse has been observed. Achillion presented three posters at AASLD which reported updated preclinical results on ACH-3422. The in vitro results demonstrated that this nucleotide pro-drug has improved potency against genotype 3 HCV as compared to sofosbuvir. In addition, in a separate poster presentation, Achillion reported that ACH-3422 displays additive to synergistic activity when combined with ACH-3102 or sovaprevir, Achillion's Phase 2 NS3/4A protease inhibitor, in vitro. Furthermore, the high barrier to resistance for ACH-3422 was supported with the ability of the agent to block, in vitro, the appearance of resistant colonies in combination with other direct-acting antiviral agents.

Achillion Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Expects to Achieve Results in HCV Development Program

Achillion Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported loss from operations of $15,764,000 against $14,076,000 a year ago. Net loss was $15,667,000 or $0.16 per basic and diluted share against $13,919,000 or $0.14 per basic and diluted share a year ago. For the nine months, the company reported loss from operations of $47,765,000 against $45,982,000 a year ago. Net loss was $47,412,000 or $0.49 per basic and diluted share against $45,597,000 or $0.49 per basic and diluted share a year ago. For the remainder of 2014, the company expects to achieve results in its HCV development program: Present Phase 2 SVR12 results following 8-weeks of treatment with the interferon-free, ribavirin-free regimen of ACH-3102, a second-generation NS5A inhibitor, and sofosbuvir in patients with treatment-naïve genotype 1 HCV; Present three posters on ACH-3422, a uridine-analog nucleotide NS5B polymerase inhibitor prodrug, at AASLD that will detail the preclinical profile of this Phase 1 direct-acting antiviral agent for HCV; and report Phase 1 proof-of-concept results with ACH-3422 including safety following 14-day exposure in healthy volunteers and antiviral activity on treatment-naïve genotype 1 HCV patients.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACHN:US $16.43 USD +2.22

ACHN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACHN.
View Industry Companies
 

Industry Analysis

ACHN

Industry Average

Valuation ACHN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 11.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACHILLION PHARMACEUTICALS, please visit www.achillion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.